• Press

    Welcome to Karnov Group’s newsroom where you find our latest press releases. If you have questions, do not hesitate to contact us.

  • Karnov-Group
    December 30, 2021

    Increased number of shares and votes in Karnov Group AB (publ)

    As of today, 30 December 2021, the total number of shares and votes in Karnov Group AB (publ) amounts to 108,102,047 shares and 107,719,234.7 votes. 
    Read more
  • Karnov-Group
    December 14, 2021

    Karnov has carried out a directed share issue of 9,827,458 ordinary shares at a price of SEK 60.40 per ordinary share

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION TO BUY ANY SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION. Karnov Group AB (publ) (“Karnov” or “the Company”) has carried out a directed share issue of 9,827,458 ordinary shares, at a subscription price of SEK 60.40 per ordinary share, entailing proceeds of approximately SEK 594 million (the “Directed Share Issue”). The subscription price was determined through an accelerated bookbuilding procedure (the “Bookbuilding Procedure”) conducted by Carnegie Investment Bank AB (publ) (“Carnegie”), Nordea Bank Abp, filial i Sverige (“Nordea”) and Barclays Bank Ireland PLC (“Barclays” and, together with Carnegie and Nordea, the “Placement Agents”). The Directed Share Issue was oversubscribed and a large number of Swedish and international institutional investors participated in the transaction.
    Read more

Luise Gramkov de Kort

Head of Group PR
luise.dekort@karnovgroup.com
Phone:+45 22 55 77 31

Subscribe via e-mail

By subscribing to our press releases, we will process your personal information to accommodate your request. Read our Privacy Policy.